Gnosis Health Secures £250k Seed Funding for AI-Powered Chronic Care Platform

Gnosis Health Limited, a digital health company based in Newcastle Upon Tyne, has raised £250k in a seed funding round. The transaction, filed and allotted on March 27, 2026, gives the company an estimated post-money valuation of £3.2m.

Incorporated in October 2018, Gnosis Health develops technology to support patients living with complex, long-term medical issues. The company is the creator of MAXine, an artificial intelligence platform designed to help patients and healthcare professionals manage chronic conditions such as Parkinson's disease.

The primary problem Gnosis Health addresses is the lack of continuous monitoring between clinical visits for chronic disease sufferers. By integrating a patient application with conversational AI and wearable device data, the MAXine platform enables real-time symptom tracking. This data is processed to generate personalized insights, allowing clinicians to monitor disease progression and optimize care plans based on objective, continuous metrics rather than relying solely on periodic consultations.

Operating with a lean team, Gnosis Health currently lists one employee on its professional network profile. While the business is registered in the North East of England, it also notes a headquarters presence in Rochester, United States, indicating a cross-border approach to its operations. Key financial metrics, including revenue and profit figures, are not publicly available at this stage of the company's development.

The £250k seed round provides fresh capital to advance the company's product offerings. At a £3.2m valuation, the investment highlights continued backing for niche digital health solutions, though the specific investors participating in this round have not been named in the latest filings. Because the company has not disclosed prior funding rounds, direct comparisons to previous valuations cannot be made.

This capital injection aligns with ongoing activity in the UK health technology sector. The UK digital health market remains a strong draw for venture capital, with sector funding reaching approximately £1.2bn in 2025. Startups that utilize artificial intelligence to alleviate clinical workloads and facilitate remote patient monitoring continue to attract early-stage investment. By focusing on the intersection of conversational AI and wearable health data, Gnosis Health is positioned within a highly relevant segment of the current UK funding landscape.